Jiro Tashiro

Jiro Tashiro

Auto-generated profile, based on publicly available information

Jiro Tashiro

Department of Veterinary Anatomy, School of Veterinary Medicine, Tottori University, 4-101 Koyama Minami, Tottori 680-8553, Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
NINanami Irie
Nanami Irie
KMKana Mizoguchi
Kana Mizoguchi
TWTomoko Warita
Tomoko Warita
MNMirai Nakano
Mirai Nakano
KSKasuga Sasaki
Kasuga Sasaki
KWKatsuhiko Warita
Katsuhiko Warita
Metastatic melanoma has a very poor prognosis. Statins, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) inhibitors, are cholesterol-lowering agents with a potential for cancer treatment. The inhibition of HMGCR by statins, however, induces feedback, which paradoxically upregulates HMGCR expression via sterol regulatory element-binding protein-2 (SREBP2). Dipyridamole, an antiplatelet agent, is known to inhibit SREBP2 upregulation. We aimed to demonstrate the efficacy of statin–dipyridamole combination treatment in both human and spontaneously occurring canine melanoma cell lines. The half maximal inhibitory concentration (IC50) of atorvastatin showed a 68–92% reduction when combined with dipyridamole, compared with that of atorvastatin alone. In some melanoma cell lines, cell proliferation was suppressed to almost zero by the combination treatment (≥3 μM atorvastatin). Finally, the BRAF inhibitor, vemurafenib, further potentiated the effects of the combined statin–dipyridamole treatment in BRAF V600E mutation-bearing human melanoma cell lines. In conclusion, the inexpensive and frequently prescribed statin–dipyridamole combination therapy may lead to new developments in the treatment of melanoma and may potentiate the effects of vemurafenib for the targeted therapy of BRAF V600E-mutation bearing melanoma patients. The concordance between the data from canine and human melanoma cell lines reinforces this possibility.

20 July 2023 in Adipocyte
Verified
Journal Article
Open access
DCDanang Dwi Cahyadi
Danang Dwi Cahyadi
TWTomoko Warita
Tomoko Warita
NINanami Irie
Nanami Irie
KMKana Mizoguchi
Kana Mizoguchi
JTJiro Tashiro
Jiro Tashiro
KWKatsuhiko Warita
Katsuhiko Warita
Normalization is a crucial step in gene expression analysis to avoid misinterpretation. Reverse transcription-quantitative polymerase chain reaction was used to measure the expression of 10 candidate housekeeping genes in non-differentiated (ND) and differentiated (DI) 3T3-L1 cells on days 5 and 10. We used geNorm, NormFinder, BestKeeper, RefFinder, and the ∆Ct method to evaluate expression stability. The findings revealed that (1) the expression levels of the reference genes changed over time, even in non-differentiating cells, and (2) peptidylprolyl isomerase A (Ppia) and TATA box-binding protein (Tbp) were stable reference genes for 10 days in both undifferentiated and differentiated 3T3-L1 cells. Notably, the expression of known reference genes in non-differentiating cells was altered throughout the experiment.

8 July 2023 in Heliyon
Verified
Journal Article
Open access
NINanami Irie
Nanami Irie
KWKatsuhiko Warita
Katsuhiko Warita
JTJiro Tashiro
Jiro Tashiro
YZYaxuan Zhou
Yaxuan Zhou
TITakuro Ishikawa
Takuro Ishikawa
TWTomoko Warita
Tomoko Warita
Statins have anticancer effects and may be used as anticancer agents via drug repositioning. In reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays, the internal reference gene must not be affected by any experimental conditions. As statins exert a wide range of effects on cells by inhibiting the mevalonate pathway, it is possible that statin treatment might alter the expression of housekeeping genes used as internal reference genes, thereby misleading the assessment of obtained gene expression data. Here, we evaluated the expression stability of internal reference genes in atorvastatin-treated cancer cell lines. We treated both statin-sensitive and statin-resistant cancer cell lines with atorvastatin at seven different concentrations and performed RT-qPCR on 15 housekeeping genes whose expression stability was then assessed using five different algorithms. In both statin-sensitive and statin-resistant cancer cell lines, atorvastatin affected the expression of certain internal reference genes in a dose-dependent and cancer cell line-dependent manner; therefore, caution should be exercised when comparing target gene expression between cells. Our findings emphasize the importance of the validation of internal reference genes in gene expression analyses in drug treatment-based cancer research.

26 September 2026 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
JTJiro Tashiro
Jiro Tashiro
TWTomoko Warita
Tomoko Warita
KWKatsuhiko Warita
Katsuhiko Warita